SEARCH

SEARCH BY CITATION

This month, Guest Editor Jonathan Maltzman discusses how an increase in the number or potency of alloreactive regulatory T cells may lead to improvements in allograft survival, citing three recent complementary reports suggesting that this approach is moving closer to becoming a reality.